- ASSISTANT PROFESSOR Radiation Oncology
MD, University of Pennsylvania
PhD, University of Pennsylvania School of Medicine
MD, University of Pennsylvania School of Medicine
Residency, Internal Medicine
Long Island Jewish Medical Center
Residency, Radiation Oncology
Mount Sinai Hospital
Michael Buckstein, M.D., Ph.D. is a radiation oncologist specializing in the treatment of gastrointestinal tumors including the esophagus, stomach, pancreas, liver, gall bladder, bile ducts, rectum, and anus as well coronary brachytherapy. He uses many advanced techniques such Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Stereotactic Body Radiation Therapy (SBRT), and brachytherapy to maximize local control and cure of the cancer while minimizing radiation side effects to healthy tissue.
Dr. Buckstein’s primary research focus is attempting to identify causes and limit treatment related toxicity from radiation therapy. In addition to large retrospective reviews identifying factors involved in disease outcomes and toxicity, he is also heavily involved in projects using genomics to identify specific individuals at risk for developing adverse side effects from treatment. He was involved in a novel study identifying genetic factors predictive for the development of erectile dysfunction following radiation for prostate cancer. His work has resulted in multiple presentations at international meetings as well publication in peer reviewed journals.
Roentgen Resident Research Award
Radiological Society of North America
Best of ASTRO Award
New York Roentgen Society
John G. Clark Prize
University of Pennsylvania School of Medicine
2000 - 2008
Medical Scientist Training Program Fellowship
National Institutes of Health
Use of Stereotactic Body Radiation Therapy and Hepatocellular CarcinomasDr. Buckstein is the principal investigator on a study using combination trans-arterial chemo embolization (TACE) with stereotactic body radiation therapy (SBRT) as a treatment paradigm for treating large hepatocellular carcinomas. In addition, he is actively working to safely integrate SBRT into treatment paradigms for HCC.
Outcomes Based Research for Gastrointestinal MalignanciesUsing a variety of tools institutional and national based databases, Dr. Buckstein is involved with research attempting to identify treatment related predictors for outcomes and development of treatment related toxicities. He has a particular focus on understanding outcomes with patients who have Inflammatory Bowel Disease who develop a malignancy.
Identifying Genetic Predictors for Radiation Treatment Related Toxicity
Dr, Buckstein is involved in mutliple projects using Genome-Wide Association Studies (GWAS) to identify individual genetic differences that might predict for the development of radiation toxicity. This will ultimately allow physicians to personalize therapy to each individual, potentially minimizing toxicity and optimizing therpeutic outcomes.
Avarbock A, Avarbock D, Buckstein M, Wang ZM, Rubin H. Functional regulation of the opposing (p)ppGpp synthetase/hydrolase activities of RelMtb from Mycobacterium tuberculosis.. Biochemistry 2005; 44: 9913-23.
Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23: 162-75.
Buckstein M, He J, Rubin H. Characterization of nucleotide pools as a function of physiological state in Escherichia coli. J Bacteriol 2008; 190: 718-26.
Ko EC, Forsythe K, Buckstein M, Kao J, Rosenstein BS. Radiobiological rationale and clinical implications of hypofractionated radiation therapy. Cancer Radiother 2011; 15: 221-9.
Snyder KM, Stock RG, Buckstein M, Stone NN. Long-term potency preservation following brachytherapy for prostate cancer. Brit J Urol Int 2012; 110: 221-5.
Kerns KL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, DeRuysscher D, Guido D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS. A Two-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Erectile Dysfunction Following Radiotherapy for Prostate Cancer. Int J Rad Bio Phys 2012; 85: e21-28.
Buckstein M, Kerns SL, Forsythe K, Stone N, Stock RG. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma. Brit J Urol Int 2013; 111(3Pt B): E43-7.
Buckstein M, Carpenter TJ, Stone N, Stock RG. Long term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years follow up. Urology 2013; 81(2): 364-368.
Patel V, Buckstein M, Perini R, Hill-Kayser C, Svoboda J, Plastaras JP. CT and PET/CT surveillance after combined modality treatment of supradiaphragmatic Hodgkin Lymphoma: a clinical and economic perspective. Leuk Lymphoma 2013;.
Stock RG, Buckstein M, Li J, Stone NN. The relative importance of hormonal therapy and biologic effective dose in optimizing prostate brachytherapy treatment outcomes. Brit J Urol Int 2013;.
Marshall RA, Stone N, Buckstein M, Stock R. Treatment Outcomes and Morbidity Following Definitive Brachytherapy with or without External Beam Radiation for the Treatment of Localized Prostate Cancer: 20 year experience at Mount Sinai Medical Center. Urol Oncol 2013;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Buckstein did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
Kravis Children Floor 1 st
1184 Fifth Avenue
New York, NY 10029
1184 Fifth Ave. 1st Floor
New York, NY 10029
- Monday 9:00am - 5:00pm
- Tuesday 9:00am - 5:00pm
- Wednesday 9:00am - 5:00pm
- Thursday 9:00am - 5:00pm
- Friday 9:00am - 5:00pm
- 1199 National Benefit Fund
- Access Meicare
- Aetna HMO
- Aetna Managed Choice
- Aetna Open Choice
- Aetna POS
- Aetna PPO
- Aetna Select Choice
- Aetna U.S. Healthcare - HMO
- Blue Cross/ Blue Shield
- CIGNA Healthcare HMO
- Cigna - PPO
- Emblem Health
- HIP Medicaid
- Health Insurance Plan (HIP)
- HealthFirst HMO Medicaid
- HealthFirst HMO Medicare
- MetroPlus Health Plan
- MultiPlan, Inc.
- Oxford Freedom
- Oxford Liberty
- Senior Plan
- United Health Care - Mount Sinai Top Tier
- United Health Care Empire Plan
- United Healthcare
- United Healthcare Medicare
- United Payors and United Providers
- UnitedHealthcare Community Plan
- VNS Medicare
- Master Card
- American Express
- Personal Check